Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry, FDA Agree On Draft User Fee Commitment Letter

This article was originally published in The Gray Sheet

Executive Summary

Draft commitment and legislative language come one month after agreement “in principle” on MDUFA III reauthorization.

You may also be interested in...



PDUFA First: Fees To Support US FDA Device Center Staff

To enhance combination product reviews, drug-fee revenue will pay for related positions in the agency's Center for Devices and Radiological Health.

PDUFA First: Fees To Support Device Center Staff

To enhance combination product reviews, drug fee revenue will pay for related positions in CDRH.

FDA Proposes To Exempt Dozens Of Devices From 510(k) Requirements

FDA plans to exempt an array of class II and class I medical devices from premarket submission requirements because the devices are sufficiently well understood and do not present risks that require premarket notification review to assure their safety and effectiveness.

Related Content

Topics

UsernamePublicRestriction

Register

MT031016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel